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ABSTRACT 
 
Health is a state of complete harmony of the body, mind and spirit. When one is free from 
physical disabilities and mental distractions, the gate of the soul open. 
 
Non-adherence to prescribed antipsychotic medications places patients with 
schizophrenia at a greatly increased risk of illness exacerbation and rehospitalization. The 
use of antipsychotic medication in the treatment of schizophrenia is well established and 
there is overwhelming evidence from clinical trials to demonstrate the benefits of these 
drugs for patients.  Poor adherence to medication regimens is common, contributing to 
substantial worsening of disease, death, and increased health care costs. Practitioners 
should always look for poor adherence and can enhance adherence by emphasizing the 
value of a patient's regimen, making the regimen simple, and customizing the regimen to 
the patient's lifestyle. Asking patients non judgmentally about medication-taking behavior 
is a practical strategy for identifying poor adherence.  
 
Patients who have difficulty maintaining adequate adherence need more intensive 
strategies than do patients who have less difficulty with adherence, a more for giving 
medication regimen, or both. Innovative methods of managing chronic diseases have had 
some success in improving adherence when a regimen has been difficult to follow. New 
technologies such as reminders through cell phones and personal digital assistants and 
pillboxes with paging systems may be needed to help patients who have the most 
difficulty meeting the goals of a regimen. 
 
The monthly relapse rates are estimated to be 3.5 % per month for patients on 
maintenance neuroleptics and 11% per month for patients who have discontinued their 
medication. Post discharge noncompliance rates in community settings are estimated to be 
7.6 % per month. These estimates were entered into a survival analysis model to determine 
the real world relapse rate. The utility of neuroleptics are substantial. Being able to give 
each patient the appropriate dosage of the right treatment should enhance not only its 
immediate efficacy, but also compliance and therefore long term efficacy. 
 
This study aims to assess the attitudes and risk factors associated with compliance 
and noncompliance among patients with Schizophrenia. The objective of the study was to 
assess the attitude and the risk factors associated with compliance and non compliance of 
neuroleptic treatment. A descriptive research design was adopted for this study. The study 
was conducted in Raju Hospital at Chennai. Out patients and in patients with 
Schizophrenia who fulfilled the inclusive criteria were assessed using modified  
standardized tools which consists reasons of medication influences {ROMI} scale, Drug 
attitude inventory scale. Ethical aspects were considered throughout the study. 
 
Analysis revealed that the percentage level  of  risk factor among compliance and 
non-compliance client.47(94.0%)  client have mild influence  and 3(6%) of clients have 
moderate influence irrespective of compliance and non compliance,AS and  18% of clients 
have unfavorable attitude, 82% of client have moderately favorable attitude. 
 
The psychiatric nurse, as a nurse educator should aim at   providing information to 
patients about both their illness and medication with the goal of increasing understanding 
and promoting compliance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER – I  
INTRODUCTION 
 
  The non-compliance with maintenance neuroleptic treatment is a major barrier to 
the effective treatment of Schizophrenic disorders and also delivery of health care. The 
medication compliance in patients with Schizophrenia had been predicted by the patient’s 
subjective response to treatment and attitudes towards antipsychotics. In this study, 
Attitude towards antipsychotic medication is significantly affected by the factors such as 
financial obstacles, substance abuse, negative relations with therapists, denial of illness 
etc. 
 
Estimating compliance rates in people with schizophrenia has proved difficult for 
two reasons. Firstly, there is no agreed definition of compliance - definitions vary from 
complete cessation or verbal refusal to any significant deviation from prescription, 
including dosage errors or failure to attend appointments. Secondly, there is no valid way 
of measuring compliance. Rates of compliance have been measured using a number of 
different methods. 
.  
 
Problems with non-compliance appear in all areas of medicine which closely 
related with treatment outcome. Factors associated with non-compliance can be identified 
in the patient, his network, the illness, the physician, the treatment setting and the 
medication itself (Blackwell, 1976).  In   schizophrenia, the patients are often incapable in 
recognizing their symptoms and seeking medical help. On the other hand, many symptoms 
of schizophrenia may result in distorted views about the purpose of both medication and 
other forms of psychiatric treatment. 
 
  Problems with compliance are common in all areas of medicine (Blackwell, 1976). 
It has been defined as the extent to which a person's behavior is in line with the medical 
advice given (Sackett & Haynes, 1976). Compliance is a multi- factorial phenomenon 
representing the patient's contribution to the treatment of illness.  It is a complex 
phenomenon representing a patient's contribution to the management of illness (Sackett & 
Haynes, 1976; Babiker, 1986). It comprehends a wide variety of behaviours: failure to 
enter a treatment programme, premature termination of therapy and incomplete 
implementation of instructions, like drug prescriptions.  
 
Studies evaluating compliance or adherence issues in psychiatry have focused on 
drug treatment, non-attendance in outpatient treatment, rehabilitation programmes, and 
self- discharge from hospital against medical advice. Rates of non-compliance in 
psychotic disorders have been reported to vary between 11 to 18% (Johnson, 1984; Kane, 
1985; Ayuso-Gutierrez & del Rio Vega, 1997). The contributing factors of compliance in 
psychotic disorders can be divided in medication-related, patient-related and 
environmental components (Fenton, Blyler & Heinssen, 1997; Kampman & Lehtinen, 
1999). Most of the studies deal with schizophrenia and related disorders, and a few with 
unselected groups of psychotic patients. 
 
In general, psychiatric disorders may have a negative stigma among people, and 
negative attitudes towards psychiatric drugs are common both in patients and their 
relatives. In previous studies, the medication related factors of compliance in psychoses 
have been explored comprehensively, whereas the patient-related and other factors, such 
as the doctor-patient relationship, psychosocial treatment programmes or the accuracy of 
diagnostics   received less attention. 
 
BACKGROUND OF THE STUDY 
 Schizophrenia has long been recognized as the most severe and disabling of 
psychiatric illness. It is not just the clinical picture but the overall decline in the patients 
functioning that is relevant. Adherence to medication regimens has been monitored since 
the time of Hippocrates, when the effects of various portions were recorded with notations 
of whether the patient had taken them or not. Even today, patients' self-reports can simply 
and effectively measure adherence. 
 
Adherence to (or compliance with) a medication regimen is generally defined as 
the extent to which patients take medications as prescribed by their health care providers. 
The word "adherence" is preferred by many health care providers, because "compliance" 
suggests that the patient is passively following the doctor's orders and that the treatment 
plan is not based on a therapeutic alliance or contract established between the patient and 
the physician. Both the terms are imperfect and uninformative descriptions of medication-
taking behavior. Unfortunately, applying these terms to patients who do not consume 
every pill at the desired time can stigmatize these patients in their future relationships with 
health care providers.  
 
The language used to describe how patients take their medications needs to be 
reassessed, but these terms are still commonly used. Regardless of which word is 
preferred, it is clear that the full benefit of  many effective medications that are available 
will be achieved only if patients follow prescribed treatment regimens reasonably , closely 
and intervene effectively in Schizophrenia. 
 
There is no question that adherence to medication is essential to maximizing 
outcomes for individual with Schizophrenia. Compliance rates may be overestimated in 
the medical literature, as compliance is often high in the setting of a formal clinical trial 
but drops off in a real world setting While adherence is poor across a wide variety of 
physical and psychiatric conditions, the consequences of poor medication adherence can 
be devastating in Schizophrenia, where the personal and societal costs of relapse are very 
high. Although we continue to develop new antipsychotic and adjunctive treatments with 
broader efficacy and improved side effects profile, levels of adherence remain alarmingly 
low. Thus we think the patients with higher rates of relapse. 
 
For decades, researchers have worked to explain the causes of poor adherence and 
to develop interventions. Unfortunately there has been remarkably little agreement 
regarding the definition of adherence or how it is best measured. Medication adherence is 
often defined as’ the extent to which a person’s behavior coincides with medical advice. 
However, different operational definitions and assessment methods identify different 
subgroups of patients. An agreed upon set of definitions and a better understanding of the 
measurement problems and how to address them are necessary, if we are going to unravel 
the complex nature of adherence. 
 
Hospitalization may benefit from adding depot antipsychotics to oral antipsychotic 
regimen. A United States of  America nationwide survey of 1,010 adults in 2001 found 
that 22%  have chosen  not to fill prescriptions because of the price, which is similar to the 
patients among   20% -30%. 
SIGNIFICANCE AND NEED FOR THE STUDY 
 Medication compliance is one of the most difficult challenges in the management 
of schizophrenia in India. Several studies were conducted to find out the significant 
predictors of medication noncompliance. In 2005 it is estimated that the rate of non-
compliance is about 50% during first year and 75% during second year, after the patients 
are discharged from inpatient care unit. Medication noncompliance is one of the main 
obstacles to control relapse in schizophrenia. It significantly increases the rate of relapse, 
length of hospitalization, and the risk for hospitalization in the future. The overall 
compliance rates for antipsychotic medication were lower than that of antidepressants and 
other drugs. 
 
Majority of these studies are done in developed countries. Very few literatures are 
available from India and other developing countries regarding the attitudes and reasons of 
medication compliance. The current study has tried to assess the attitudes and reasons for 
compliance as well as noncompliance among patients with schizophrenia. It can provide 
basis for planning effective interventional strategies to the mental health professionals for 
improving compliance of the patient in the future. 
 
Poor adherence to medication treatment can have devastating consequences for 
patients with serious mental illness. The literature review and recommendations in a article 
concerning assessment of adherence problems in patients with serious and persistent 
mental illness, published in 2009.The expert consensus survey contained 39 questions that 
asked about defining non adherence, extent of adherence problems in schizophrenia and 
bipolar disorder, risk factors for non adherence, assessment methods, and interventions for 
specific types of adherence problems. The survey was completed by 48 experts to whom it 
was sent. When evaluating adherence, the experts considered it important to assess both 
behavior and attitude, although they considered actual behavior is most important. 
 
They also noted the importance of distinguishing  patients who are not willing to 
take medication from those who are willing but not able to take their medication as 
prescribed due to forgetfulness, misunderstanding of instructions and  financial or environ 
mental problems. Although self and physician report are most commonly used to clinically 
assess adherence, they are often inaccurate and may underestimate no adherence. 
To assess baseline predictors and consequences of antipsychotic adherence during 
the long term treatment of schizophrenia outpatients, data were taken from the 3-year 
prospective and observational. European Schizophrenia Outpatients Health Outcomes 
[SOHO] study, in which outpatients starting or changing antipsychotics were assessed 
every 6 month. Physician rated adherence was dichotomized as adherence/non adherence. 
Regression models tested for predictors of adherence during follow up, and associations 
between adherence and outcome measures among 6731 patients were  analysed, the  
findings  are  71.2% were  adherent and 28.8% were non adherent over 3 years. 
 
The strongest predictor of adherence was a month before baseline assessment. 
Other baseline predictors of adherence included initial treatment for schizophrenia and 
greater social activities. Baseline predictors of non-adherence were alcohol dependence 
and substance abuse. On adherence was significantly associated with an increased risk of 
relapse, hospitalization and suicide attempts. 
 
In India a study (1999) shows that individual with schizophrenia  who have 
discontinued antipsychotics in the previous 12 months,  the findings were50% improved 
but require extensive support network,10% hospitalized and unimproved, 25% partially 
recovered,10% dead. 
 
Discontinuation of the initiated treatment was used as criterion for effectiveness 
and patient’s drug attitude was shown to be predictive for non-adherence or 
discontinuation of long term treatment in schizophrenia. As the noncompliance leads to 
relapse in schizophrenia, the investigator felt that it is essential to assess the attitude and 
reasons for noncompliance of neuroleptic treatment and it will be very useful to the health 
professionals. 
 
TITLE 
Assessment of attitude on risk factors associated with compliance and non-
compliance of neuroleptic treatment among patients with schizophrenia. 
 
 
 
STATEMENT OF THE PROBLEM   
A study to assess the attitude on risk factors associated with compliance and non-
compliance of neuroleptic treatment among patients with schizophrenia in Raju Hospital at 
Chennai. 
 
OBJECTIVES 
1. To assess the attitude on compliance and non compliance of neuroleptic treatment 
among  patients with schizophrenia. 
2. To assess the risk factors on compliance and non-compliance of neuroleptic 
treatment   among  patients with schizophrenia. 
3. To associate the level of risk factors on compliance and non-compliance of 
neuroleptic treatment with the demographic variables. 
4. To associate the level of attitude on compliance and non-compliance of neuroleptic 
treatment with the demographic variables. 
 
VARIABLES 
Research Variable 
Independent variable 
Attitude on compliance and non-compliance with neuroleptic treatment. 
 
Dependent variable  
Risk factors on compliance and non-compliance  with neuroleptic treatment. 
 
Demographic Variables 
Age, sex, marital status, family income, living situation, prescribed regimen and 
onset of illness. 
 
ASSUMPTIONS 
1. Non-compliance of the neuroleptic treatment has a strong influence on relapse of 
schizophrenic clients. 
2. Relapse can have long term effects on outcome of schizophrenic clients 
3. Health professional has an important role to play in guiding the family members 
regarding prevention of relapse. 
 
OPERATIONAL DEFINITIONS 
Attitude 
Attitude is the hypothetical construct that represents an individual degree of 
behavior. 
 
Risk factors 
Risk factors are factors that increases a person’s chances of developing disease or 
disorder 
 
Compliance 
The degree of consistency and accuracy with which a patient follows the 
prescribed regimen. 
 
Non-compliance 
Disregarding of a prescribed treatment plan 
 
Neuroleptic treatment 
Neuroleptic or an antipsychotic is a psychiatric medication primarily used to 
manage psychosis particularly used in schizophrenic disorder. 
 
Relapse 
The recurrence of a disease after apparent recovery 
 
Patient with schizophrenia 
The person who is diagnosed as having Schizophrenia by the Psychiatrist 
 
DELIMITATION 
This study is delimited to the schizophrenic clients who have relapse episode 
 
 
PROJECTED OUTCOME 
1. The assessment and identification of attitude regarding noncompliance of 
neuroleptic treatment   will help the nurses to take meticulous actions in advance, 
which will prevent relapse in. 
2. The findings would provide an insight regarding areas where the patients and 
family members would change the behavior regarding compliance and 
noncompliance of neuroleptic treatment. 
3. And these findings can help to plan for many education programmers so for it can 
prevent the relapse in schizophrenic clients. 
 
SUMMARY 
This chapter contains background of the study, significance and need for the study, 
title, statement of the problem, objectives and variables of the study, assumptions, 
operational definitions, delimitations and projected outcome. 
 
ORGANIZATION OF THE REPORT 
 The following chapter contains 
Chapter – II  - Review of literature and conceptual framework. 
Chapter – III  - Methodology. 
Chapter – IV  - Analysis and interpretation. 
Chapter – V  - Discussion. 
Chapter – VI  - Summary, implications, recommendations and limitations 
 This is followed by reference and appendices. 
 
 
 
 
 
 
 
 
 
 
CHAPTER – II 
REVIEW OF LITERATURE 
 
The review of literature is based on extensive survey of journals, nursing books 
and international nursing journals. A review of literature relevant to the study was 
undertaken which helps the investigator to develop deep insight in to the problem and gain 
information what has been done in the past. 
 
An extensive review of literature was done by the investigator to a broad 
foundation for the study and conceptual framework to proceed with the study under the 
following headings. 
 
Section – A:   Literature regarding non compliance of neuroleptic treatment. 
Section – B: Literature regarding risk factors associated with non compliance of 
neuroleptic treatment. 
Section – C: Literature regarding attitude on compliance of neuroleptic treatment. 
 
SECTION–A: LITERATURE REGARDING NON-COMPLIANCE OF 
NEUROLEPTIC TREATMENT 
 
Kennedy, et al., (2000) conducted a study which showed that there is also good 
evidence that the prophylactic use of antipsychotic medication prevents relapse.  
 
Taylor, et al., (2000) conducted a study which showed that prescriptions for 
antipsychotics are often inappropriate, resulting in unwanted and unnecessary side-effects. 
Non-compliance suggests that the patient has not done what they were told by a mental 
health professional i.e. stopped taking medication.  
 
Marder, et al., (1999) conducted a study which demonstrated that compliance with 
antipsychotic medication is generally poor and not taking medication is associated with a 
substantial increase in rehospitalizations and a poorer outcome in people with 
schizophrenic disorders. 
 
Marley,  et  al., (1999)   found   that  the  modern mental health care is concerned 
and working with patients,  consequently it has been proposed that 'concordance' should 
replace the use of the word 'compliance'. Concordance emphasizes patient rights, the need 
for information and the importance of two-way communication and decision-making. In  
contrast with a compliance, they  suggested that patients have the right to make decisions 
(such as stopping medication) even if clinicians do not agree with the decision. The focus 
of this review is therefore to examine interventions that improve the taking of prescribed 
antipsychotic medication. 
 
Repper & Perkins (1998)  highlighted that the importance of language in mental 
health and suggested  the use of words like compliance infer that patients are passive 
recipients of health care who should be obey the instructions from professionals. 
 
Cramer & Rosenheck (1998) proposed an average non-compliance rate of 
approximately 42%, a finding that is similar to rates in other mental and physical 
disorders. 
 
Kemp, et al., (1997) have proposed that the so called 'revolving door phenomena' 
can be almost exclusively attributed to repeated non-compliance. Kisling (1994) has 
argued that if patients were completely compliant with their medication, relapse rates 
would fall to about 15%.  Currently 50% of patients relapse within a year of achieving 
remission. However, the poor compliance can be attributed solely to the patient's failure to 
do what clinicians have told them  must be juxtaposed with evidence that professionals 
often do not carry out their own responsibilities regarding medication.  
 
Thomas, et al., (1997) conducted a study which showed that neuroleptic efficacy 
accounted  for 60% of the rehospitalization costs and neuroleptic noncompliance for 
roughly 40 percent. The economic burden due to loss of efficacy is relatively higher 
during the first post discharge year, whereas the burden from noncompliance is higher in 
the second year. Because loss of medication efficacy, medication noncompliance act 
synergistically on relapse and substantial inpatient cost savings can be realized by linking 
better pharmacologic treatments of schizophrenia with more effective strategies to manage 
medication noncompliance. 
 
Kemp & David (1996) showed a significant relationship between insight and 
compliance. In schizophrenia, insight - defined as awareness of illness, an ability to 
recognize symptoms as part of an illness and acceptance of treatment - has also been 
associated with compliance. A number of studies have been examined the relationship 
between insight and compliance with generally consistent results, despite substantive 
differences in operational definitions of insight. 
 
Churchill (1995) highlighted that the rates of compliance have been measured  by 
using a number of different methods; however, none has proved satisfactory. These 
include physicians' assessment and patients' self-report, pill counts, and urine and blood 
assays. These methods of assessment are not always reliable. Patient self-report and 
physician assessment are inaccurate, both consistently overestimating compliance. Pill 
counts are more reliable, but it is impossible to tell whether the patient has actually 
ingested the medication. Urine testing for drug with a long half-life will tend to 
overestimate compliance. As most neuroleptics have a relatively long half-life, blood 
assay is likely to prove more reliable. However, the degree of compliance is impossible to 
determine and therefore blood assays can only be used as a criterion for current 
compliance. 
 
McEovy, et al., (1989) conducted a study which proved that a number of 
interpersonal (such as the therapist's ability to listen and empathize with the patient) and 
relationship factors (liking and trusting the therapist, and the patient's level of 
involvement in treatment decisions including discussion of the patient's beliefs, concerns 
and expectations have been shown to correlate with compliance in patients with mental  
disorders. 
 
Appelbaum & Gutheil (1980) who interviewed 40 patients who refused 
antipsychotic medication during a 3- month period. In that ,Psychotic psychopathology, 
especially paranoia, suspi- ciousness, grandiosity and delusional beliefs about medication, 
were highlighted as influencing compliance . 
 
Quit-kin, et al., (1978) used clinician judgement to determine compliance and 
observed  only 10% of patients were non-compliant with their medication over a 12-
month period. 
Van Putten et al. (1976) observed that grandiose delusions were more common in 
non- compliant patients. The more severe a patient's psychopathology, the worse  in  their 
compliance. 
 
Renton, et al., (1963) examined this relationship in a study of 132 patients. They 
reported that the severity of patients' symptom at the time of discharge was significantly 
associated with future adherence. 
 
Wolff & Colacino, (1961), using patient interviews over a 6-month period, 
reported that 73% of patients were non-compliant. 
 
SECTION – B: LITERATURE REGARDING RISK FACTORS ASSOCIATED TO 
NON COMPLIANCE 
Miner, et al., (1997) conducted a study which showed that substance abuse seems 
to be a strong predictor of non-compliance in psychosis, especially in men . More 
specifically, non-compliance has correlated more clearly with heavy than with slight 
alcohol and with the use of marijuana. 
 
Laura D, (1992) suggested that non adherence to prescribed antipsychotic 
medications places patients with schizophrenia at a greatly increased risk of illness 
exacerbation and re hospitalization.  
 
Stanly, et al., (1990) found that the factors most consistently associated with            
non-adherence included poor insight, negative attitude or subjective response toward 
medication, previous non-adherence, substance abuse, shorter illness duration, inadequate 
discharge planning or aftercare environment, and poorer therapeutic alliance. Findings 
regarding an association between adherence and medication type were inconclusive, 
although few studies explored this relationship. Other factors such as age, gender, 
ethnicity, marital status, education level, neurocognitive impairment, severity of psychotic 
symptoms, severity of medication side effects, higher antipsychotic dose, presence of 
mood symptoms, route of medication administration, and family involvement were not 
found to be consistent predictors of non-adherence.  
 
Hemanth, et al., (1987) conducted a study and found the predominant reasons for 
discontinuation were: patient unconvinced about need for treatment (32%), poor efficacy 
(32%) and adverse events (7%). Only half of those experiencing poor efficacy were 
switched to another drug. Many patients appear to discontinue therapy for illogical reasons 
and this may be amenable to intervention. 
 
Clara, (1987) found that Medication noncompliance was significantly associated 
with substance abuse. Subjects who abused substances, had no outpatient contact, and 
were noncompliant with medication had significantly greater symptom severity than other 
groups.  Substance abuse is strongly associated with medication noncompliance among 
patients with schizophrenia. The combination of substance abuse, medication 
noncompliance, and lack of outpatient contact appears to define a particularly high-risk 
group. 
 
Marland, et al.,(1987) conducted  a study at Rutgers University in New Brunswick, 
New Jersey, USA,  to identify predictors of noncompliance among  schizophrenic clients. 
They highlighted patients with schizophrenia at high risk for medication noncompliance 
after acute hospitalization are characterized by a history of medication noncompliance. 
The recent substance use, difficulty recognizing their own symptoms, a weak alliance with 
inpatient staff, and family who refuse to become involved in inpatient treatment. 
 
Wieden, et al., (1986) conducted a study which showed that contemporaneous 
side-effects had a weak but significant impact on compliance. 
 
 Yung ,et al.,(1985) conducted a study  in Swiss, at Institute of Mental Health 
among 126 patients. In that (5.8%) were no longer receiving neuroleptic, the most 
common reasons for discontinuing treatment were actual side effects (61%) or the fear of 
side effects (25%). Overall, 16% of patients did not receive   pharmacological therapy in 
accord with official Swiss guidelines.  
 
Van Putten, (1974) demonstrated that an increased incidence of bradykinesia, 
dystonia and tremor, but not akathisia, was associated with patients who were reluctant to 
take medication. In this study, akathisia was not associated with non-compliance. 
  
SECTION – C: LITERATURE REGARDING ATTITUDE ON COMPLIANCE OF 
NEUROLEPTIC TREATMENT 
Walburn, et al., (2001) conducted a study which concluded that the patients 
showed more positive attitudes to depot medication compared with oral administration. 
 
Val Enstein, et al., (2001) conducted a study which proved there is a need for 
quality improvement with prescribing guidelines of depot medications. 
 
Smith, et al.,(1997) conducted a study which proved that the family members' 
awareness of the patient's illness is also connected to better compliance. 
 
Fenton, et al.,(1997) conducted a study which showed negative attitudes towards 
antipsychotic medication predict non-compliance. 
 
 Smith, et al.,( 1997) found that male patients had lower adherence compared with 
women in a skill training programme for chronic schizophrenia patients after relapse. 
 
Razali and Yahya (1995), highlighted to consider the medication to be helpful in 
treating their illness and have a positive attitude toward medication. Conversely, 
noncompliant patients have no reason for taking medication because they are consider 
themselves to be ill, or they may see taking the medication as the wrong way to solve their 
problems. 
 
Bebbington & Kuipers (1994) conducted a study which showed that the supportive 
family environment has been reported to have a positive effect on compliance. 
 
Draine & Solomon, (1994) conducted a study which proved social activity has 
been related to more positive attitudes towards medication in outpatient care (but to 
poorer compliance with long-term rehabilitation patients. 
 
Adams & Howe (1993) examined the factors that were likely to predict good 
compliance in 44 psychotic inpatients. The greater number of indirect benefits of 
medication (i.e. 'keeps me out of hospital' or 'it allows me to make new friends'), the more 
compliant patients had. 
Awad, (1993) conducted a study which proved a negative change in the subjective 
state during medication has been associated with negative attitudes and impaired 
compliance.  
 
            Drake, et al., (1991) highlighted that living alone and poor housing increase the 
risk of medication non-compliance.  
 
Wilms, et al., (1985) suggested that attitudes and illness concepts can be 
understood as the sum of opinions, interpretations, explanations, and predictions with 
regard to the state of an individual's health. These attitudes are largely independent of 
psychopathology and should not be confused with psychopathological symptoms such as 
"lack of insight into the illness.  
 
  Chan, (1984) suggested that there are a number of factors that influence patients' 
decisions about taking antipsychotic medication. Some factors are clearly more influential 
than others; insight, beliefs about treatment and side-effects appear to be particularly 
important.   
 
Being clinically common and crucial in relation to outcome, problems with 
compliance arouse from multiple reasons. In psychotic disorders compliance involves the 
specific factors, such as side-effects of anti-psychotic medication, attitudes towards 
treatment and insight regarding symptoms, or disturbances in cognitive functioning. Most 
of the previous studies have focused on the weight of medication effects and side-effects. 
Similarly, attitudes towards medication, and the roles of psychopathology, insight and 
substance abuse are all well established as important factors regarding non-compliance. 
 
 
 
 
 
 
 
 
 
PART – II 
CONCEPTUAL FRAMEWORK 
 
 
Conceptual framework based on Pender’s Health Promotion Model. 
 
This section deals with conceptual framework adopted for this study. A conceptual 
framework provides the investigator the guidelines to proceed in attaining the objectives 
of the study based on a theory. These are a schematic representation of the steps, activities 
and outcome of the study. 
 
This model is concerned with the changing of behavior, developed and tested by 
Nola Pender, et al. The health promotion model is used to predict the likelihood of a 
person’s engaging in health promoting behavior. 
 
According to health promotion model, 7 cognitive /perceptual factors reflect on 
individual belief. These factors include individual belief, the importance of health, 
perceived threat to health, perceived control of health, perceived health status, perceived 
benefits of health promoting behavior and person’s barriers to health promoting behavior. 
 
Individual Belief 
The schizophrenic clients who are on antipsychotics, many of them having 
negative attitude towards antipsychotic medication, so that there is no progression even 
after taking medication. 
 
Perceived threat to health  
Due to discontinuing the antipsychotics, the clients are prone to relapse 
 
Perceived control of health 
After perceiving the threat of relapse the client will modify his behavior into   
positive attitude 
 
 
Importance of health 
The schizophrenic clients strive to promote their health by being an adherent, so 
that they can decrease their relapse. 
 
Perceived Health Status 
The chronically ill schizophrenic clients experiencing relapse. 
 
Perceived benefits of health promoting behavior 
The schizophrenic clients accepting the importance of taking medication of 
antipsychotics and became a compliance so that there is no relapse. 
 
Persons barrier to health promoting behavior 
If schizophrenic clients not taking medication regularly because of negative 
attitude and risk factors, they will experience relapse. 
 
The conceptual framework also includes modifying factors. The modifying factors 
are the demographic variables are age, sex, income, and marital status, onset of illness, 
prescribed medication, and living situation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER – III 
METHODOLOGY 
 
 This chapter deals with research methodology which was undertaken for gathering 
and organizing data for investigation. It includes description of research approach, 
research design, variables under study, setting of the study, population, sample, sampling 
technique, sampling criteria, sample size, description of the tool, and pilot study.  
 
Research methodology is a way to systematically solve a research problem. It is a 
science of studying how research is done scientifically. Methodology is a significant part 
of the research under which the researcher undertaken.  The purpose of the present study is 
to assess the attitude on compliance and non-compliance of neuroleptic treatment among 
patients with schizophrenia that have at least one relapse episode. 
 
RESEARCH APPROACH:  
The research approach chosen for the study was descriptive research approach. It 
was designed to obtain information regarding attitude on risk factors associated to 
compliance and non compliance of neuroleptic treatment among schizophrenic clients. 
 
RESEARCH DESIGN 
 The research design adopted for this study was non experimental descriptive 
research design.  
 
RESEARCH VARIABLE  
Independent Variable 
Attitude on compliance and  non-compliance with neuroleptic treatment. 
 
Dependent Variable  
Risk factors on compliance and non-compliance with neuroleptic treatment. 
 
Demographic Variables 
Age, sex, marital status, family income, living situation, prescribed regimen  and 
onset of illness. 
SETTING OF THE STUDY 
 Study setting is the general physical location in which data collection takes place 
(Polit & Beck 2004). 
 
 The study was conducted in an outpatient and inpatient psychiatric department of 
Raju Hospital, Chennai. It is located in the center of city. It is 30 bedded hospitals. There 
50% of psychiatric patients are coming for neuroleptic treatment. 
 
POPULATION  
Target Population 
  The target population is comprised of all schizophrenic patients who have at least 
one relapse episode. 
 
Accessible Population 
 It refers to the aggregate of cases which conform to the designed criteria and which 
is accessible to the researcher as the pool or objects.  The accessible population comprised 
of all the schizophrenic patients who have at least one relapse episode and who are 
attending inpatient department and outpatient department during the study period in Raju 
Hospital, Chennai. 
 
SAMPLE 
  The sample comprised of all the schizophrenic patients who had at least one 
relapse episode and who were attending inpatient department and outpatient department 
during the study period in Raju Hospital, Chennai. 
 
SAMPLE SIZE 
The sample size of the study comprised of 50 schizophrenic patients who had 
atleast one relapse episode. 
 
SAMPLING TECHNIQUE  
 In this study Non- Probability Convenient Sampling technique was used to select 
subjects as they fulfilled the inclusion criteria. 
CRITERIA FOR SAMPLE SELECTION 
Inclusion Criteria 
1. Schizophrenic patients who had at least one relapse episode. 
2. Able to speak Tamil or English. 
 
Exclusion Criteria 
 Schizophrenic patients who were non-willing to participate in the study. 
 
METHOD OF DEVELOPING THE TOOL 
The following steps were carried out in developing the questionnaire 
1. Literature review 
2. Expert’s opinion 
 
Literature Review 
 Literature from nursing books, journals, periodicals, published and unpublished 
research studies and news paper articles were reviewed and used to develop the tool. 
 
Experts Opinion 
The investigator had discussed with the experts and incorporated their valuable 
suggestions in developing the tool. 
 
DESCRIPTION AND VALIDITY OF THE TOOL 
 The tool consists of two items. The content validity of the tools obtained by 
submitting the tool to the experts including 2 psychiatrists and 3 nursing experts for their 
opinion and suggestions. The changes were made according to expert’s suggestions and 
opinion. 
 
TOOL I: 
 Demographic variables which consists of 7 items. Verbal response was obtained 
from the psychiatric patients who have at least one relapse episode regarding age, sex, 
marital status, living situation, prescribed medication, income, onset of illness. 
 
 
TOOL II: 
Part – A  
 The attitude towards neuroleptic treatment was assessed using modified 30 item 
drug attitude inventory(DAI).It is a self-report questionnaire in which each item ticked’ 
yes’ is rated +1 and items ticked ‘no’s rated as 0.The positive scores and negative scores 
are calculated and the total score will be positive score minus negative score. Positive total 
score indicates positive attitude and negative total score indicates negative attitude towards 
neuroleptic treatment. 
 
Part – B  
The risk factors of neuroleptic treatment were assessed by using  modified rating of 
medication influence (ROMI) scale. Subjective reasons of medication compliance, on 
compliance were assessed using 20 item (ROMI) scale  
 
SCORING KEY 
For assessing attitude  modified(DAI) scale 
30 item questions were used 
Yes- +1 for positive attitude 
No-   0 for negative attitude 
Less than 50%- mild 
50-75 %- moderate 
Above 75 %-high 
For assessing risk factors modified (ROMI) scale 
 20 items question were used 
Reasons for compliance (7 open ended questions) 
None-   1 
Mild-2 
Strong-3 
The same scoring will be used for reasons for noncompliance (13 open ended 
questions) 
 
PILOT STUDY 
Pilot study was conducted at Aashiyana  Hospital at Anna Nagar, Chennai, during 
the period of 22.04.2010 to 24.04.2010.The investigator selected 5 samples who fulfilled 
inclusive criteria. The researcher collected the data through Interview schedule. On an 
average it took 30-40 minutes for each person to collect the data. There was no practical 
difficulties met by the investigator and the tools were considered to be reliable and 
appropriate. Hence the same procedure was decided to be followed in the main study. 
 
The analysis taken for the above 5 patient resulted in reliability r=0.86 which 
helped in the further up gradation of the study. 
 
PROCEDURE FOR DATA COLLECTION 
Procedure for data collection for main study was conducted in Raju Hospital at 
T.Nagar, Chennai. The investigator collected totally 50 samples in which each day 5 
patients were undergone this data collection procedure. Brief introduction was given 
regarding the purpose of research. The data was collected by using modified standardized 
tools and modified 3 point likert scale. Ethical aspects were conducted throughout the 
study. 
Date Number of samples 
15.05.10  to  15.06.10 50 
 
DATA ANALYSIS PROCEDURE 
Both descriptive and inferential statistics were used. 
 
Descriptive Statistics 
Analysis of socio demographic data of schizophrenic patients were done in terms 
of  frequency and percentage distribution. 
 
Mean and standard deviation was used to complete degree of influence regarding 
attitude and risk factors of compliance and non compliance of neuroleptic treatment. 
 
Inferential Statistics 
Chi-square test was used to associate the attitude and risk factors with the 
demographic variable. 
 
 
CHAPTER – IV 
DATA ANALYSIS AND INTERPRETATION 
 
This chapter deals with the analysis and interpretation of data collected from 50 samples to 
assess the level of attitude on compliance and non-compliance of neuroleptic treatment 
among patients with schizophrenia. 
 
Data analysis is as evaluation of information and its pertinence to the study 
variable. Data analysis helps the researcher to organize, summaries, evaluate, interpret and 
communicate the numerical facts.   
 
Descriptive and inferential statistics were used for the analysis of the data. As per 
the objectives of the study, the interpretation has been tabulated and organized as follows. 
 
ORGANIZATION OF THE DATA 
Section A : Socio demographic variable of the schizophrenic clients.  
 
Section B : Assessment of level of risk factors of compliance and non-compliance of 
neuroleptic treatment.  
 
Section C :    Assessment of level of attitude on compliance and non-compliance of 
neuroleptic treatment.                                                                                      
 
Section D :   Association of level of risk factors on compliance & non-compliance of 
neuroleptic treatment among schizophrenic clients with their demographic 
variables. 
 
Section E :   Association of level of attitude regarding compliance and non-compliance 
of neuroleptic treatment among schizophrenic clients with their 
demographic variables. 
 
 
 
SECTION A 
Table-1: Frequency and percentage distribution of demographic variables 
n = 50 
Age No. % 
20-30 yrs 25 50 
31-40yrs 15 30 
41-50yrs 4 8 
above 50 yrs 6 12 
Sex     
Male 45 90 
Female 5 10 
Marital  status     
Married 19 38 
Single 31 62 
Widow 0 0 
Living situation     
Supervised 42 84 
Un supervised 8 16 
Prescribed medication     
Neuroleptic medication 42 84 
Non neuroleptic medication 1 2 
Neuroleptic with other medication 7 14 
 Family Income     
<Rs.3000 2 4 
Rs.3000-5000 13 26 
Rs.5000-10000 25 50 
>Rs.10000 10 20 
Onset of illness     
Before 6 month 11 22 
1 - 3yrs 19 38 
3 - 5yrs 10 20 
above 5yrs 10 20 
 
Table-1 shows the frequency and percentage distribution of demographic variables 
of schizophrenic clients. 
 
With regard to age, 25(50%) clients were comes under 20 to 30 years, 15(30%) 
were 31-40 years, 4(8%) were 4-50 years and remaining 6(12%) were above 50 years of 
age. 
With regard to sex, 45(90%) of schizophrenic clients were male and 5(10%) were 
female. 
Regarding marital status, 19(38%) of clients were married, 31(62%) were single. 
Regarding living situation, 42(84%) were supervised by their parents or guardian, 
8(16%) were Unsupervised. 
With regard to prescribed medication 42(84%) were comes under neuroleptic 
treatment, 1(2%) were comes under the non-narcoleptic medication, 7(14%) were belongs 
to neuroleptic with other medication. 
Regarding income, 2(4%) of clients belongs to the income of <Rs.3000, 13(26%) 
were belongs to the income of Rs.3000 -5000, 25(50%) were Rs.5000-10000, 10(20%) 
were come under the income of above Rs.10000. 
Regarding onset of illness,11(22%) clients onset were before 6 months, 19(38%) 
were1-3 years,10(20%) were 3-5 years and remaining  10(20%) were above 5 years. 
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Fig.2: Percentage distribution of age of the sample 
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 Fig.3:Percentage distribution of sex of the sample 
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Fig.4: Percentage distribution of marital status of the sample 
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Fig.5: Percentage distribution of living situation of the sample 
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Fig. 6: Percentage distribution of prescribed medication of the sample 
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Fig.7: Percentage distribution of income of the sample 
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Fig.8: Percentage distribution of onset of illness of the sample 
 
 
 
 
 
 
 
 
 
 
 
SECTION B 
Table 2: Frequency and percentage distribution of level of compliance and non-
compliance 
n = 50 
Variables 
Mild 
(<50%) 
Moderate 
(50 – 75%) 
High 
(>75%) 
No. % No. % No. % 
Compliance 45 90.0 5 10.0 0 0 
Non-Compliance 49 98.0 1 2.0 0 0 
Overall 47 94.0 3 6.0 0 0 
 
Table 2 shows the frequency and percentage distribution of level of compliance 
and non-compliance of neuroleptic treatment. 
 
The table illustrates that 90% of clients were having mild influence and 5% of 
clients were having moderate influence on compliance.  In non compliance  49 % of 
clients  were having  mild influence  and  1 % were having  moderate influence  on  non 
compliance. overall 47(94.0%)  client have mild influence and 3(6%) of clients have 
moderate influence  irrespective  of compliance  and  non compliance of neuroleptic 
treatment. 
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Fig.9: Percentage distribution of level of risk factors 
 
 
 
 
 
 
 
 
 
 
Table 3: Mean and standard deviation of compliance and non-compliance 
n = 50 
Variables Mean S.D 
Compliance 14.98 2.30 
Non-Compliance 18.04 4.49 
Overall 33.02 5.39 
 
 Table 3 shows the mean and standard deviation of compliance and non-
compliance regarding risk factors for neuroleptic treatment. 
 
The above table clearly indicates that mean score of risk factors compliance is 
14.98 with standard deviation of2.30 and for non-compliance  the mean score is18.04 with 
standard deviation of 4.49. 
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Fig.10: Comparison of mean scores of compliance and non-compliance 
 
 
 
 
 
 
 
 
 
SECTION C 
Table 4:  Frequency and percentage distribution of level of attitude. 
n= 50 
Variable 
Mild 
(<50%) 
Moderate 
(50 – 75%) 
High 
(>75%) 
No. % No. % No. % 
Attitude 9 18.0 41 82.0 0 0 
 
 
 Table 4 shows percentage distribution of level of attitude on compliance and non-
compliance. 
 
18% of clients have unfavorable attitude, 82% of client have moderately favorable 
attitude. 
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Fig.11: Percentage distribution of level of attitude 
 
 
 
 
 
 
 
 
 
 
 
Table 5: Mean and standard deviation of attitude. 
n= 50 
Variable Mean S.D 
Attitude 16.44 2.47 
 
Table 5 shows that the mean and standard deviation of attitude regarding 
compliance and non-compliance of neuroleptic treatment. The mean score of attitude is 
16.44 with standard deviation of 2.47. 
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Fig.12: Comparison of mean scores of risk factors and attitude 
 
 
 
 
 
 
 
 
 
 
Table 6: Assesment of level of risk factors of compliance and non-compliance 
n= 50 
Reasons for compliance 
Degree of influence 
None Mild Strong 
1.Percieved daily benefit 22(44%) 10(20%) 18(36%) 
2.Positive relation with 
prescribing clinician 
17(34%) 15(30%) 18(36%) 
3.positive relation with  
therapist 
21(42%) 14(28%) 15(30%) 
4.Positive family belief 10(20%) 14(28%) 26(52%) 
5.Relapse prevention 27(54%) 9(18%) 14(28%) 
6.Pressure/force 33(66%) 17(34%)  
7.Fear of rehospitalisation 28(56%) 14(28%) 8(16%) 
 8. No perceived daily benefit 33(66%) 10(20%) 7(14%) 
9. Negative relation with    
prescribing clinician 
38(76%) 7(14%) 5(10%) 
10.Negative relation with 
therapist 
38(76%) 7(14%) 5(10%) 
11.Practitioner opposed to  
meds 
37(74%) 8(16%) 5(10%) 
12.Family/ friend opposed to 
meds 
36(72%) 5(10%) 9(18%) 
13.Access to treatment 
problems 
31(62%) 15(30%) 4(8%) 
14.Stigma over meds 25(50%) 15(30%) 4(8%) 
15.Financial obstacles 31(62%) 12(24%) 7(14%) 
16.Substance abuse 33(66%) 12(24%) 5(10%) 
17.Denial of illness 29(58%) 16(32%) 5(10%) 
18.Medication currently 
unnecessary 
29(58%) 14(28%) 7(14%) 
19. Distressed by side effects 26(52%) 19(38%) 5(10%) 
20.Desire rehospitalisation 34(68%) 9(18%) 7(14%) 
 
Table 6 shows that assessment of level of risk factors of compliance and non 
compliance. 
In  reasons  for compliance,  44 %  were  none, 20 % were  mildly influenced, 36 
% were  strongly influenced  by  perceived   daily benefit. 
With   regard to positive relation with prescribing clinician, 34% were none, 30 % 
were mildly influenced and 36 % were strongly influenced   
           In   positive   relation with therapist, 42% were none, 28 % were mildly influenced, 
and 30 % were strongly influenced.  
          With regard to positive family belief, 20% were none, 28% were mildly influenced 
and 52 % were strongly influenced. 
           Regarding relapse prevention, 54% were none, 18% were mildly influenced, 28% 
were strongly influenced. 
          With regard to pressure/force 66 % were mildly influenced, and 34 % were 
moderately influenced. 
          Regarding   fear of rehospitalization,56 %  %  were  none, 28 % were mildly 
influenced, 16% Were  strongly influenced  . 
 
In  reasons  for  non  compliance,   no  perceived daily benefit , 66%  were  none, 20%  
were  mildly influenced & 14% Were  strongly influenced. 
 
With regard to negative relation with  prescribing  clinician, 76% %  were  none, 
14% were  mildly influenced, 10% Were  strongly influenced. 
 
Regarding negative relation with therapist, 76% were none, 14% were mildly 
influenced, and 10 % were  strongly influenced  . 
 
Considering   the   practitioners opposed to meds, 74% were none, 16% were 
mildly influenced, and 10 % were strongly influenced. 
 
Considering family/ friend opposed to meds, 72% were none, 10% were mildly 
influenced and 18 % were strongly influenced. 
 
Regarding access to treatment problem, 62% were none, 30% were mildly 
influenced and 10 % were strongly influenced. 
Considering stigma over meds, 74% were none, 16% were mildly influenced, and 
8 % were strongly influenced. 
 
Regarding financial obstacles, 62% were none, 24% were mildly influenced, and 
14 % were strongly influenced. 
 
With regard to substance  abuse,  66% were none, 24% were mildly influenced, 
and 10 % were strongly influenced. 
 
Regarding denial of illness, 58% were none, 32% were mildly influenced, and 10% 
were strongly influenced. 
 
Considering medication currently unnecessary, 58% were none, 28% were mildly 
influenced and 14 % were strongly influenced. 
 
With regard to distressed   by side effects, 52% were none, 38% were mildly 
influenced and 10 % were strongly influenced. 
 
Regarding desire rehospitalization, 68% were none, 18% were mildly influenced, 
and 14% were strongly influenced. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7: Association of level of attitude with the demographic variables. 
n = 50 
Demographic Variables 
Mild 
(<50%) 
Moderate 
(50 – 75%) 
Severe 
(>75%) 
Chi-Square 
Value 
No. % No. % No. % 
Age       
2
 = 11.337 
d.f = 3 
S* 
20-30 yrs 3 6.0 22 44.0 - - 
31-40yrs 2 4.0 13 26.0 - - 
41-50yrs 0 0 4 8.0 - - 
above 50 yrs 4 8.0 2 4.0 - - 
Sex       2 = 0.015 
d.f = 1 
N.S 
Male 8 16.0 37 74.0 - - 
Female 1 2.0 4 8.0 - - 
Marital  status       
2
 = 0.101 
d.f = 1 
N.S 
Married 3 6.0 16 32.0 - - 
Single 6 12.0 25 50.0 - - 
Widow - - - - - - 
Living situation       2 = 0.195 
d.f = 1 
N.S 
Supervised 8 16.0 34 68.0 - - 
Un supervised 1 2.0 7 14.0 - - 
Prescribed medication       
2
 = 8.543 
d.f = 2 
S* 
Neuroleptic medication 5 10.0 37 74.0 - - 
Non neuroleptic medication 0 0 1 2.0 - - 
Neuroleptic with other med 4 8.0 3 6.0 - - 
Income       
2
 = 3.471 
d.f = 3 
N.S 
<Rs.3000 0 0 2 4.0 - - 
Rs.3000-5000 3 6.0 10 20.0 - - 
Rs.5000-10000 6 12.0 19 38.0 - - 
>Rs.10000 0 0 10 20.0 - - 
Onset of illness       
2
 = 4.617 
d.f = 3 
N.S 
Before 6 month 1 2.0 10 20.0 - - 
1 - 3yrs 2 4.0 17 34.0 - - 
3 - 5yrs 4 8.0 6 12.0 - - 
above 5yrs 2 4.0 8 16.0 - - 
*p<0.05, S – Significant, N.S – Not Significant 
 
Table 7 clearly shows the association of level of attitude with the demographic 
variables. 
The age and prescribed medication are significantly associated with attitude of 
compliance and non compliance of neuroleptic treatment.  
 Sex, marital status, living situation, income and onset of illness are not 
significantly associated with attitude of compliance and  non compliance of  neuroleptic 
treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8: Association of level of risk factors with the demographic variables. 
n= 50 
Demographic Variables 
Mild 
(<50%) 
Moderate 
(50 – 75%) 
Severe 
(>75%) 
Chi-Square 
Value 
No. % No. % No. % 
Age       
2
 = 2.246 
d.f = 3 
N.S 
20-30 yrs 1 2.0 24 48.0 - - 
31-40yrs 2 4.0 13 26.0 - - 
41-50yrs - - 4 8.0 - - 
above 50 yrs - - 6 12.0 - - 
Sex       2 = 1.931 
d.f = 1 
N.S 
Male 2 4.0 43 86.0 - - 
Female 1 2.0 4 8.0 - - 
Marital  status       
2
 = 1.113 
d.f = 1 
N.S 
Married 2 4.0 17 34.0 - - 
Single 1 2.0 30 60.0 - - 
Widow - - - - - - 
Living situation       2 = 0.608 
d.f = 1 
N.S 
Supervised 3 6.0 39 78.0 - - 
Un supervised - - 8 16.0 - - 
Prescribed medication       
2
 = 1.030 
d.f = 2 
N.S 
Neuroleptic medication 2 4.0 40 80.0 - - 
Non neuroleptic medication 0 0 1 2.0 - - 
Neuroleptic with other med 1 2.0 6 12.0 - - 
Income       
2
 = 0.655 
d.f = 3 
N.S 
<Rs.3000 - - 2 4.0 - - 
Rs.3000-5000 1 2.0 12 24.0 - - 
Rs.5000-10000 1 2.0 24 48.0 - - 
>Rs.10000 1 2.0 9 18.0 - - 
Onset of illness       
2
 = 1.127 
d.f = 3 
N.S 
Before 6 month 1 2.0 10 20.0 - - 
1 - 3yrs 1 2.0 18 36.0 - - 
3 - 5yrs 1 2.0 9 18.0 - - 
above 5yrs - - 10 20.0 - - 
N.S – Not Significant 
Table 8 shows that age, sex, marital status, sex and income are not significant with 
level of risk factors of compliance of neuroleptic treatment. 
CHAPTER – V  
DISCUSSIONS 
 
 
This chapter discusses the findings of the study derived from statistical analysis. 
The problem stated was a study to assess the attitude on risk factors associated to 
compliance and noncompliance of neuroleptic treatment in Raju Hospital, Chennai. 
 
  Very few study only conducted in India regarding attitude on medication non-
compliance and compliance which measured the attitudes and risk factors of patients.  
Compliance in this study is defined as degree to which the patient consistently follows the 
instruction given by the doctor regarding medication and treatment. For various reasons 
measuring compliance status accurately is a difficult process. 
 
The first objective is to assess the attitude on compliance and non-compliance. 
The attitude of schizophrenic patients towards medication and treatment are 
measured by modified (DAI) Drug attitude inventory. In this current study majority of 
patients have negative attitude towards medication irrespective of the compliance/non-
compliance of the status. 
 
A study regarding attitude on compliance and non-compliance were conducted in 
New Delhi in 2009.In that 38.7% of patients and family members had a positive attitude 
towards medication and treatment. 
 
In this study majority were having moderately   favorable   attitude that is 82 % 
and   18% were having unfavorable attitude (negative attitude). No one is having favorable 
attitude (positive attitude) irrespective of compliance and non-compliance. The attitude 
score of DAI represent an indirect representation of compliance. 
 
 
 
 
The second objective is to assess the risk factors of compliance and non-compliance 
of neuroleptic treatment. 
The response to the modified ROMI open ended questions were grouped into 
reasons for compliance which consists of 7 question and reasons for non-compliance 
consists of 13 questions. 
 
Babied 1986, Bellinger ET all done the research on medication compliance. In that 
10% are estimated to be compliant and 76% of patients are estimated to be non-compliant.  
 
This current study shows that 90% of clients were having mild influence and 5% of 
clients were having moderate influence on compliance.  In non compliance  49 % of 
clients  were having  mild influence  and  1 % were having  moderate influence  on  non 
compliance. Overall 47(94.0%) clients have mild influence and 3(6%) of clients have 
moderate influence irrespective of compliance and non compliance of neuroleptic 
treatment. 
 
It is likely that non-compliance rates are under estimated. And as it is an alarming 
finding, it requires great attention. 
 
The third objective was to associate the level of risk factors on compliance & non-
compliance of neuroleptic treatment with the demographic variables. 
Number of risk factors is identified for non-compliance. One previous study 
revealed that Kelly et al, 2001 have found that side effects account for only 10% of the 
variance in self-reported compliance. In this study 48% of clients were influenced by side 
effects. 
 
Positive relation  with  treating  therapist  18%  of  the  people  were  strongly 
influenced. In positive family belief 52% were strongly influenced. In 1992, Vaughn and 
Leaf 1996 have found that the cost of relapses not only by the patient but also the family 
members who often supervising, and their maintenance of relationship also influenced by 
the patient. 
 
BARCO et al 1987 have considered stigma over medication, financial obstacles 
and side effects influence compliance. In this current study, 25% stigma over meds, 30% 
substance abuse, 22% denial of illness and 32% were desired to be rehospitalised were 
influence the compliance. 
 
The fourth objective was to associate the level of attitude on compliance and non-
compliance of neuroleptic treatment with the demographic variables. 
A number of demographic factors have been identified as bearing a relationship 
with non-compliance in those with a diagnosis of schizophrenic clients.  
 
Gender is another demographic factor Atwood et al in 1995 found that men are less 
likely to comply than women. In this study women are less likely to comply than men. In 
this study also gender is a significant relation with attitude on compliance of neuroleptic 
treatment.  Lenin et al. suggested that prescribed medication plays an important role in 
compliance. In my study also prescribed medication d.f=2, p is less than 0.05, which is  
significantly associated with level of attitude on compliance. 
 
One study Tunnicliffe et al., (1992) found that lack of family support has been 
cited as an important predictor, but marital status does not influence.     In this study also 
marital status does not influence much. But other factors like age and prescribed 
medications are much more influence and significant.  Yung et al in 1997 found that 20 to 
30 years of age people are associated with non-compliance. 
 
In conclusion many patients are having negative attitude on compliance. Regarding 
risk factor, the factors which are significantly influence should be incorporated into any 
programmed designed to improve over all attitude. 
 
 
 
 
 
 
 
 
 
 
CHAPTER – VI 
SUMMARY, RECOMMENDATIONS, NURSING IMPLICATIONS  
AND LIMITATIONS 
 
SUMMARY 
The research problem was stated as “A study to assess the attitude on risk factors 
associated with compliance and non-compliance of neuroleptic treatment among patient 
with schizophrenia in Raju Hospital at Chennai. 
 
The objectives were: 
1. To assess the attitude on compliance and non compliance of neuroleptic treatment 
among patients with schizophrenia. 
2. To assess the risk factors on compliance and non-compliance of neuroleptic 
treatment among patients with schizophrenia 
3. To associate the level of risk factors on compliance & non-compliance of 
neuroleptic treatment with the demographic variables. 
4. To associate the level of attitude on compliance and non-compliance of neuroleptic 
treatment with  the demographic variables 
 
The Assumptions made were 
1. Non-compliance of the neuroleptic treatment has a strong influence on relapse of 
schizophrenic clients. 
2. Relapse can have long term effects on outcome of schizophrenic clients  
3. Health professional has an important role to play in guiding the family members 
regarding prevention of relapse. 
 
The major findings of the study were  
 Out of 50 patients, 90% of clients were having mild influence and 5% of clients 
were having moderate influence on compliance. In non compliance, 98% of clients were 
having mild influence and 2% of clients were having moderate influence on non 
compliance. Regarding attitude, 18% of client have unfavorable attitude and 82 % of 
clients were having moderately favorable attitude. As the above findings proved that the 
assumptions made in this study were true. 
NURSING IMPLICATIONS 
The investigator had derived the following implications from the study which are 
vital concern in the field of nursing practice, nursing administration, nursing education, 
and nursing research. 
 
Nursing Practice 
1. The psychiatric nurse as a service provider, as a care giver, should periodically 
organize awareness programme  through counseling and  in service educational 
programme  within the clinical settings. 
2. The nurse must implement information, education, communication (IEC) to 
provide awareness to the health professionals. 
3. As a service provider the nurse should provide self-care modules, personal 
management module on drug compliance. 
4. The  community nurse, as a service provider should conduct mass education 
programmed on medication compliance and non-compliance and its positive, 
negative attitude of  patients and family and its impact, appropriately assigned 
audio visual aids 
 
Nursing Education 
1. Nurse educator should actively involve in the process of organizing continuing 
education like conducting in-service education in their institutions regarding 
compliance and noncompliance of neuroleptic treatment. 
2. Make available literature related to neuroleptic drug and its compliance and 
noncompliance, impact, risk factors, related disorders and its management. 
 
Nursing Administration 
1. As an administrator the psychiatric nurse should design formal teaching 
programmed on drug compliance for family in the selected community. 
2. Provide opportunity for nurses to attend training programmed. 
3. The nurse must be instrumental at point out relevant policies of the state and 
central level to ensure effective program to educate the public and facilitate 
optimal allocation for implementing the programmed. 
4. Create an intersect oral network to control disorders. 
Nursing Research 
1. Encourage further studies on medication compliance and noncompliance among 
family members and patients, caregivers in different settings. 
2. More research needs to be conducted on the aspects of medication compliance and 
noncompliance, risk factors, attitude, education programmed and in effective 
therapies. 
 
RECOMMENDATIONS 
A similar study can be replicated on a large sample at state level. 
 
LIMITATION  
Minor difficulties found during the study period as the patients were not co-
operating. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
BOOKS 
Agarwal VM, A. K. & Gupta. Textbook of Schizophrenia. (9
th
 ed). Philadelphia: 
W.B.Saundars Company. 
 
Ahuj Niraj (2002). A short textbook of psychiatry. (5
th
 ed). New Delhi: Jaypee Medical 
Publishers (P). Ltd. 
 
Amador, XF & David, AS (2004). Awareness of Illness in Schizophrenia and related 
disorders. (2
nd
  ed) . Oxford University Press. 
 
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental 
Disorders. (4
th
  ed). 
 
Ann Boyed (2000). Textbook of Psychiatry. Philadelphia: J.B Lippincot Company. 
 
Basavanthappa BP (1998). Nursing Research. (3
rd
 ed). Mumbai: Jaypee Brothers 
Publishers (P) Ltd. 
 
Ben Green (1996). Problem Based Psychiatry. (2
nd
 ed). Mumbai: Jaypee Publishers (P) 
Ltd. 
 
Bhatia MS (1999). Essentials of Psychiatry. (2
nd
 ed). New Delhi: C.B.S Publishers and 
Distributors. 
 
Gail .W Stuart and Michele .T Laria (2005). Principles and Practice of Psychiatric  
Nursing. (8
th
 ed). Mosby Publication. 
 
Garef and Woodworth (1981). Textbook of Statistics in Education. Bombay: Simons  
Publishing Company. 
 
Gupta CB and Gupta (1991). An Introduction of Statistical Methods. New Delhi: Vikas 
Publishing Company. 
 
Kaplan and Sadock’s (1994). Synapsis of Psychiatry. (10th ed). New Delhi: B.I.Waverly 
Private Limited. 
 
Keltner and Folds (1993). Text book of Psychotropic Drugs. Missouri: Mosby Publishers. 
 
Kurt JL (1994). A short textbook of Antipsychotics. London: International Publication. 
 
Lambert .M, Naber .D (2004). Current Schizophrenia. London: Science Press In Press. 
 
Mahajan BK (1999). Methods in Biostatistics. New Delhi: Jaypee Publishers. 
 
Polit and Hungler (1999). Textbook of Nursing Research. (6
th
 ed). Philadelphia: Lippincot 
Company. 
 Sadock BJ and Sadock VA (2005). Comprehensive Textbook of Psychiatry. (8
th
 ed).  
Philadelphia: Lippincot Company. 
 
Sadock BJ and Sadock VA (2005). Comprehensive Textbook of Psychiatry. (7
th
 ed).  
Philadelphia: Lippincot Company. 
 
Sadock Kaplan (1999). Comprehensive Textbook of Psychiatry. (10
th
 ed). Philadelphia: 
Lippincot Company. 
 
Sreevani .R (2005). A Guide to Mental Health and Psychiatric Nursing. (2
nd
 ed). New 
Delhi: Jaypee Publication. 
 
Treece EW and Treece JW (1986). Elements of Research in Nursing. London: C.V.Mosby 
Publishing Company. 
 
Williams and Joyce MN. Short textbook of Psychotropic Drugs. (3
rd
 ed). Philadelphia: 
Lippincot Company. 
 
JOURNALS 
Aga VM, Agarwal, AK & Gupta, SC (1995). The relationship of insight to 
psychopathology in schizophrenia: a cross sectional study. Indian Journal of Psychiatry, 
37, 129 -135.   
 
Boby (2000). Disruption of two novel genes by a translocation co-segregating with 
schizophrenia. Hum. Mol. Genet, 9, 1415-1423. 
 
De Zoysa N (2008). A cross-sectional study of patients' perspectives on adherence to 
antipsychotic medication: depot versus oral. J Clin Psychiatry, 69, 1548 – 56. 
 
Dolder CR, Lacro JP (2002). Antipsychotic medication adherence: Is there a difference 
between typical and atypical agents? Am J Psychiatry, 159, 103-8. 
 
Dittmann RW (2007). Association of subjective well-being, symptoms, and side effects 
with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry, 68,     
75-80. 
 
Flaum XF, Andreasen .M, (1994). Awareness of illness in schizophrenia and 
schizoaffective and mood disorders. Archives of General Psychiatry, 51, 826 -836. 
 
Friedman, JH & Kasapis, C (1996). Suicidal behavior in schizophrenia and its relationship 
to awareness of illness. American Journal of Psychiatry, 153, 1185 -1188. 
 
I. & Zador, G. (1988). Clinical symptomatology and drug compliance in schizophrenic 
patients. Acta  Psychiatrica Scandinavica, 77, 74 -76.  
 
Jacker WW, Boter. Effectiveness of antipsychotic drugs in first-episode schizophrenia and 
Schizophrenia Form Disorder, 80-82. 
 
Kuipers .E (2008). A large-scale validation study of the Medication Adherence Rating  
Scale  (MARS). Schizo-phr Res, 100, 53. 
 
Lam EY, (1997). How are psychotic symptoms perceived?  A comparison between 
patients, relatives and the general public. Australian and New Zealand Journal of 
Psychiatry, 31, 756 -76 
 
Lieberman JA, McEvoy JP (2005). Effectiveness of antipsychotic drugs in patients with 
chronic schizophrenia. N Engl J Med, 353, 1209.  
 
Marley (2009). Second-generation versus first-generation anti-psychotic drugs for 
schizophrenia: a meta-analysis. Lancet, 373, 31 – 41. 
  
Naber D, Karow A, Lambert M. (2005). Subjective well-being under the neuroleptic 
treatment and its relevance for compliance. Acta Psychiatr Scand, 427, 29 – 34.  
 
Strauss XF, Yale DH, SA (1991). Awareness of illness in schizophrenia. Schizophrenia 
Bulletin, 17, 113 -132. 
 
Strauss, DH, Yale, SA (1993). Assessment of insight in psychosis. American Journal of 
Psychiatry, 150, 873 – 879. 
 
Voruganti LP, Baker LK, Awad AG (2008). New generation antipsychotic drugs and 
compliance behaviour. Curr Opin Psychiatry, 21, 133 – 9. 
 
Wittorf .A (2007). Antipsychotic medication adherence in schizophrenia. Psychiatr Clin 
North Am, 30, 437. 
 
Yung Klingberg S (2008). Collaboration in outpatient antipsychotic drug treatment: 
analysis of potentially influencing factors. Psychiatry Res, 161, 225-34. 
 
 
WEBSITES 
http:/www.pubmed.com 
http:/www.madhealth.com 
http:/www.healthscience.com 
http:/www.med.psych.org.in 
http:/www.wiki.com 
http:/www.webcomindia.com 
 
 
 
 
 
  
 
 
APPENDIX – A  
LIST OF EXPERTS FOR CONTENT VALIDITY OF THE TOOL 
 
 
1. Mrs.Shanthi,R.N.,R.M., M.Sc (N).,  
Professor, Mental Health Nursing, 
SRMC College of Nursing,  
Porur, Chennai. 
 
2. Mrs.Neelakshi, R.N., R.M., M.Sc (N),. 
Professor, Mental Health Nursing,  
SRMC College of Nursing,  
Porur, Chennai. 
 
3. Mr.Manigandan , MSW., 
Social Worker , 
 Raju Hospital,  
Chennai. 
 
4. Mrs.Grace, R.N., R.N., M.Sc (N),. 
Professor, Mental Health Nursing,  
Matha College of Nursing,  
Chennai. 
 
5. Dr.K.Vijayakumar, M.B.B.S., DPM., 
Raju Hospital,  
Chennai. 
 
 
 
 
 
 
LETTER SEEKING EXPERTS OPINION FOR CONTENT VALIDITY 
 
From 
Ms.W.Jerone L. Benedicta 
 M.Sc.(N) II Year, 
 Vel R.S Medical College – College of Nursing, 
 Avadi, Chennai – 600 062. 
 
To 
Respected Madam/Sir, 
Sub: Requisition for expert opinion on suggestion for content validity of the tools. 
 
I am Ms. W.Jerone L. Benedicta, a student of M.Sc.(Nursing)- II year at Vel R.S 
Medical College - College of Nursing, Avadi, Chennai – 62, affiliated to 
Dr.M.G.R.Medical University, Chennai. 
 
As a partial fulfillment of the requirement in the M.Sc. Nursing Programme,       I 
have to complete a dissertation the topic I have selected is “A study to assess the attitude 
on risk factors associated with compliance and noncompliance of neuroleptic 
treatment among patients with schizophrenia, in Raju Hospital at Chennai”. 
 
Herewith I am sending the developed tools for content validity and for your expert 
opinion & valuable suggestions. 
 
 
   Thanking you, 
 
Yours sincerely, 
 
 
(W.JERONE .L BENEDICTA) 
Enclosures:         
1. Statement and objectives of the study 
2. Blue print of the tools 
3. Content validity certificate 
 
  
 
 
CERTIFICATE FOR CONTENT VALIDITY 
 
 
 This is to certify that the tools developed by Ms.W.Jerone L. 
Benedicta, M.Sc. Nursing student Vel R.S. Medical College – College of 
Nursing, Chennai on the topic, “A study to assess the attitude on risk 
factors associated with compliance and noncompliance of neuroleptic 
treatment among patients with schizophrenia, in Raju Hospital at 
Chennai” is validated by the undersigned and she can proceed with this tool 
to conduct the main study. 
 
 
Place : Chennai 
Date :         Signature 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX – B 
INTRODUCTION 
 
Dear Participants, 
 I am Miss.Jerone L. Benedicta, M.Sc.(N) II Year student from Vel R.S.Medical 
College – College of Nursing, Avadi, Chennai. I would like to assess the attitude on risk 
factors associated with compliance and non-compliance of neuroleptic treatment among 
patients with schizophrenia. I request you to participate in the study. A rating scale will be 
used to collect data regarding your attitude and risk factors on compliance and non 
compliance of neuroleptic treatment. I assure you that the responses given by you will be 
used only for my study purpose.  So I request you to kindly give your full co-operation 
and willingness. 
 
Thanking you. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEMOGRAPHIC VARIABLES 
1.Age 
20-30 yrs 
31-40yrs 
41-50yrs 
above 50 yrs 
2.Sex 
Male 
Female 
3.Marital  status 
Married 
Single 
Widow 
4.Living situation 
Supervised 
Un supervised 
5.Prescribed medication 
Neuroleptic medication 
Non neuroleptic medication 
Neuroleptic with other medication 
6. Family Income 
<Rs.3000 
Rs.3000-5000 
Rs.5000-10000 
>Rs.10000 
7.Onset of illness 
Before 6 month 
1 - 3yrs 
3 - 5yrs 
above 5yrs 
 
 
MEDICATION QUESTIONNAIRE 
S.No. Contents True False 
1. I don't need to take medication once I feel better   
2. For me, the good things about medication outweigh the bad   
3. I feel strange, "doped up", on medication   
4. Even when I am not in hospital I need medication regularly   
5. If I take medication, it's only because of pressure from other 
people 
  
6. I am more aware of what I am doing, of what is going on 
around me, when I am on medication 
  
7. Taking medications will do me no harm   
8. I take medications of my own free choice   
9. Medications make me feel more relaxed   
10. I am no different on or off medication   
11. The unpleasant effects of medication are always present   
12. Medication makes me feel tired and sluggish   
13. I take medication only when I feel ill   
14. Medications are slow-acting poisons   
15. I get along better with people when I am on medication   
16. I can't concentrate on anything when I am taking medication   
17. I know better than the doctors when to stop taking 
medication 
  
18. I feel more normal on medication   
19. I would rather be ill then taking medication   
20. It is unnatural for my mind and body to be controlled by 
medications 
  
21. My thoughts are clearer on medication   
22. I should keep taking medication even if I feel well   
23. Taking medication will prevent me from having a 
breakdown 
  
24. It is up to the doctor to decide when I should stop taking 
medication 
  
25. Things that I could do easily are much more difficult when I 
am on medication 
  
26. I am happier and feel better when I am taking medications   
27. I am given medication to control behaviour that other people 
(not myself) don't like 
  
28. I can't relax on medication   
29. I am in better control of myself when taking medication   
30. By staying on medications I can prevent myself getting sick   
RATING OF MEDICATION INFLUENCE SCALE 
PART I: REASONS FOR COMPLIANCE 
"ARE YOU WILLING TO TAKE YOUR MEDICATION BECAUSE": 
1. PERCEIVED DAILY BENEFIT  
You believe the medicine helps you feel better? 
2. POSITIVE RELATION WITH PRESCRIBING CLINICIAN NA 
Your relationship with your prescribing doctor influences you? 
3. POSITIVE RELATION WITH THERAPIST  
Your relationship with your therapist influences you? 
4. POSITIVE FAMILY BELIEF 
Someone in your family or a friend believes that you should  
take medicine? 
5. RELAPSE PREVENTION 
You believe taking medication prevents your illness or symptoms NA from returning? 
6. PRESSURE/FORCE 
You are pressured or forced to take medication? 
7. FEAR OF REHOSPITALIZATION 
You are afraid of being rehospitalized? 
8. NO PERCEIVED DAILY BENEFIT  
You believe medication does not help you feel better?  
9. NEGATIVE RELATION WITH CLINICIAN 
Your bad relationship with your prescribing doctor influences  
you?  
10. NEGATIVE RELATION WITH THERAPIST 
Your bad relationship with your therapist influences you? 
11. PRACTITIONER OPPOSED TO MEDS 
One of your practitioners does not believe you should be taking the medication? 
12. FAMILY/FRIEND OPPOSED TO MEDS 
Someone whose opinion is important to you is against your taking the medication? 
13. ACCESS TO TREATMENT PROBLEMS 
You have difficulty getting to your appointments, and/or difficulty getting meds? 
14. EMBARRASSMENT OR STIGMA OVER MEDS/ILLINESS 
You feel embarrassed about taking medication? 
15. FINANCIAL OBSTACLES 
You don't have enough money to pay for treatment or medication? 
16. SUBSTANCE ABUSE 
You would rather take other drugs or alcohol? 
17. DENIAL OF ILLNESS 
You don't believe you have a mental illness? 
18. MEDICATION CURRENTLY UNNECESSARY 
You don't believe that you currently need the medication? 
19. DISTRESSED BY SIDE EFFECTS 
The side effects of the medicine are too upsetting to you? 
20. DESIRES REHOSPITALIZATION 
You feel more comfortable in the hospital? 
None Mild Strong Not Assessable 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Ó¸×¨Ã 
 
Å½ì¸õ. 
 ¿¡ý §Åø ¬÷.±Š. ÁÕòÐÅ ¸øæÃ¢-¦ºÅ¢Ä¢Â÷ ¸øæÃ¢Â¢ø 
þÃñ¼¡õ ¬ñÎ ÓÐ¸¨Ä ¦ºÅ¢Ä¢Â÷ ¸øÅ¢ ÀÂ¢Öõ Á¡½Å¢. ¿¡ý ±ý 
ÀÊôÀ¢ý ´Õ ÀÌ¾¢Â¡¸ ÁÉ§¿¡ö Á¡üÈ ÁÕóÐ ±ÎôÀ¾ý ãÄõ 
²üÀÎõ ÀÂýÀ¡ðÎ Á¾¢ôÀ£ð¨¼ô ÀüÈ¢Ôõ «¾ý À¡÷¨Å ¦¾¡ÌôÒ 
ÀüÈ¢Ôõ ´Õ ¬ö¨Å ¿¼òÐ¸¢ý§Èý. þ¾ý ¦¾¡¼÷À¡¸ ¿¡ý ¾í¸¨Ç 
±ÉÐ ¬öÅ¢ý Àí§¸üÀ¡ÇÃ¡¸ þ¨½òÐì ¦¸¡ûÇ Á¢¸ ¾¡ú¨ÁÔ¼ý 
§¸ðÎì¦¸¡û¸¢§Èý. þ¾ý ¦¾¡¼÷À¡¸ ¿¡ý §¸ðÌõ §¸ûÅ¢¸ÙìÌ ºÃ¢Â¡É 
¯í¸û À¾¢¨Ä ¦¾Ã¢Å¢ì¸×õ. ¯í¸û À¾¢¨Ä ¿¡ý ±ý ¬öÅ¢ü¸¡¸ 
ÁðÎ§Á ÀÂý ÀÎòÐ§Åý ±ýÚ ¯Ú¾¢ÂÇ¢ì¸¢§Èý.  
 
    ¿ýÈ¢! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
¾¸ÅÄ¡Ç÷ Å¢ÅÃõ 
¸£úì¸ñ¼ Å¢ÀÃí¸ÙìÌ ¾ì¸ Å¢¨¼ÂÇ¢ì¸×õ: 
1. ÅÂÐ 
«) 20 – 30 ÅÕ¼í¸û 
¬) 31 – 40 ÅÕ¼í¸û 
þ) 41 – 50 ÅÕ¼í¸û 
®) 50-ìÌ §Áø 
 
2. þÉõ / À¡ø 
«) ¬ñ 
¬) ¦Àñ 
 
3. ¾¢ÕÁ½ Å¢ÀÃõ 
«) ¾¢ÕÁ½Á¡ÉÅ÷ 
¬) ¾¢ÕÁ½Á¡¸¡¾Å÷ 
þ) Å¢¾¨Å 
 
4. Å¡Øõ Ýú¿¢¨Ä 
«) ¸ñ¸¡½¢ôÒìÌû þÕôÀÅ÷ 
¬) ¸ñ¸¡½¢ôÒ þøÄ¡¾Å÷ 
 
5. ÁÉ§¿¡ö (¯ÇôÀ¢½¢) Á¡üÈ ÁÕóÐ 
«) ÁÉ§¿¡ö Á¡üÈ ÁÕóÐ ÁðÎõ 
¬) ÁÉ§¿¡ö «øÄ¡¾ ÁÕóÐ 
þ) ÁÉ§¿¡ö Á¡üÈ ÁÕóÐ §ÅÚ ÁÕóÐõ 
 
6. ÌÎõÀ ÅÕÁ¡Éõ 
«) 3000ìÌ ¸£ú 
¬) 3000 – 5000 Å¨Ã 
þ) 5000 – 10000 Å¨Ã 
®) 10000ìÌ §Áø 
 
7. §¿¡Â¢ý ¦¾¡¼ì¸õ 
«) 6 Á¡¾ò¾¢üÌ 
¬) 1 – 3 ÅÕ¼í¸û 
þ) 3 – 5 ÅÕ¼í¸û 
®) 5-ÅÕ¼í¸ÙìÌ §Áø 
ÁÕóÐ ÌÈ¢ò¾ À¡÷¨Å ÀüÈ¢Â ¦¾¡ÌôÒ 
 
Å.±ñ. ¦À¡ÕÇ¼ì¸õ ºÃ¢ ¾ÅÚ 
1 xU Kiw ¿ÄÁ¡¸ þÕôÀ¾¡¸ ¯½÷ó¾¡ø ±ÉìÌ 
ÁÕòÐÅõ njitapy;iy 
  
2 ¿øÄ Å¢„Âí¸¨Ç Å¢¼ ÁÕòÐÅò¨¾ ÀüÈ¢Â 
§Á¡ºÁ¡É Å¢„Âí¸û ¦ÀÕõ ¾¡ì¸ò¨¾ 
²üÀÎòÐ¸¢ÈÐ. 
  
3 kUe;Jfis cl;bfhs;tjhy; ehd; tpj;jpahrkhf 
czu;fpnwd; 
  
4 º¢¸¢î¨ºÂÇ¢ìÌõ §À¡Ð §À¡¨¾Â¢ø þÕôÀ¾¡¸ 
Å¢ò¾¢Â¡ºÁ¡¸ ¯½÷¸¢§Èý. 
  
5 ¿¡ý ÁÕòÐÅÁ¨ÉÂ¢ø þÕó¾¡Öõ ±ÉìÌ 
¦¾¡¼÷óÐ º¢¸¢î¨º §¾¨Å. 
  
6 ¿¡ý º¢¸¢î¨º ±ÎòÐì ¦¸¡ûÅÐ À¢ÈÃ¢ý 
ÅüÒÚò¾Öì¸¡¸ò ¾¡ý ÁÕóÐ ±ÎìÌõ §À¡Ð 
  
7 ¿¡ý ±ýÉ ¦ºö¸¢§Èý, ±ý¨Éî ÍüÈ¢ ±ýÉ 
¿¼ì¸¢ÈÐ ±ýÀ¨¾ô ÀüÈ¢ ¦¾Ç¢Å¡¸ þÕì¸¢§Èý. 
  
8 º¢¸¢î¨º ¦ÀÚÅÐ, ±ùÅ¢¾ò¾¢Öõ ±ý¨É À¡¾¢ì¸¡Ð.   
9 ¿¡ý º¢¸¢î¨º ±ÎòÐì ¦¸¡ûÅÐ ±ÉÐ 
Å¢ÕôÀò¾¢É¡ø ¾¡ý. 
  
10 º¢¸¢î¨º, ±ý¨É Á¢¸×õ þÂøÀ¡¸ þÕì¸ 
¨Åì¸¢ÈÐ. 
  
11 º¢¸¢î¨ºÂ¢ø þÕó¾¡Öõ þø¨Ä ±ýÈ¡Öõ 
Å¢ò¾¢Â¡ºõ ¦¾Ã¢ÂÅ¢ø¨Ä. 
  
12 º¢¸¢î¨ºÂ¢ý Å¢ÕõÀò¾¸¡¾ Å¢¨Ç×¸û ¦¾¡¼÷óÐ 
þÕì¸¢ÈÐ. 
  
13 º¢¸¢î¨º ±ý¨É ¸¨ÇôÀ¨¼Â ¨Åì¸¢ÈÐ. §º¡õÀ¢ 
þÕì¸î ¦ºö¸¢ÈÐ. 
  
14 ¿¡ý Å¢ÕõÒõ§À¡Ð ÁðÎ§Á ¿¡ý º¢¸¢î¨º ±ÎòÐì 
¦¸¡û¸¢§Èý. 
  
15 ÁÕóÐ ¯ð¦¸¡ûÅÐ, ¦ÁÐÅ¡¸ ¦¸¡øÖõ Å¢„õ.   
Å.±ñ. ¦À¡ÕÇ¼ì¸õ ºÃ¢ ¾ÅÚ 
16 ¿¡ý º¢¸¢î¨º ±ÎòÐì ¦¸¡ûÙõ §À¡Ð À¢ÈÕ¼ý 
¿øÄ Ó¨ÈÂ¢ø ¿¼óÐ ¦¸¡û¸¢§Èý. 
  
17 º¢¸¢î¨ºÂ¢ø þÕìÌõ§À¡Ð ±¾¢Öõ ÓØ¨ÁÂ¡¸ 
®ÎÀ¡Î þÕôÀ¾¢ø¨Ä. 
  
18 ±ô§À¡Ð º¢¸¢î¨º¨Â ¿¢Úò¾ §ÅñÎõ ±ýÚ 
ÁÕòÐÅ÷¸¨Ç Å¢¼ ±ÉìÌ ¿ýÈ¡¸ ¦¾Ã¢Ôõ. 
  
19 º¢¸¢î¨ºÂ¢ø ¯ûÇ ¦À¡ØÐ Á¢¸Á¢¸ þÂøÀ¡¸ 
þÕì¸¢§Èý. 
  
20 º¢¸¢î¨º ¦ÀÚÅ¨¾Å¢¼ §¿¡§Â¡Î þÕôÀÐ 
ÀÃÅ¡Â¢ø¨Ä. 
  
21 º¢¸¢î¨ºÂ¡ø ±ÉÐ ÁÉ¨¾Ôõ ¯¼¨ÄÔõ 
¸ðÎôÀÎòÐÅÐ þÂøÒìÌ Á¡È¡ÉÐ. 
  
22 º¢¸¢î¨º ÀüÈ¢Â º¢ó¾¨É Á¢¸×õ ¦¾Ç¢Å¡¸ ¯ûÇÐ.   
23 ¿¡ý ¿ÄÁ¡¸ þÕôÀ¾¡¸ ¯½÷ó¾¡Öõ, º¢¸¢î¨º 
±ÎòÐ ¦¸¡ûÇ §ÅñÎõ. 
  
24 º¢¸¢î¨º ¦ÀÚÅÐ, ÁÕóÐ ¯ð¦¸¡ûÅÐ ¿¡ý 
Ì¨ÄóÐ §À¡Å¨¾ ¾ÎìÌõ. 
  
25 ÁÕòÐÅ§Ã ¿¡ý ±ô¦À¡ØÐ º¢¸¢î¨º¨Â ¿¢Úò¾ 
§ÅñÎõ ±ýÚ ÓÊ× ¦ºöÂ §ÅñÎõ. 
  
26 º¢¸¢î¨ºÂ¢ø þøÄ¡¾§À¡Ð ¿¡ý ÍÄÀÁ¡¸ ¦ºöÔõ 
§Å¨Ä¸û Ü¼ Á¢¸×õ º¢ÃÁÁ¡¸ ¦¾Ã¢¸¢ÈÐ. 
  
27 ±ÉìÌ º¢¸¢î¨º «Ç¢ì¸ôÀÎÅÐ ±ÉÐ ¿¼ÅÊì¨¸ 
À¢ÈÃ¡ø º¸¢ì¸ ÓÊÂÅ¢ø¨Ä ±ýÀ¾¡ø ¾¡ý ±ÉìÌ 
º¢¸¢î¨º «Ç¢ì¸ôÀÎ¸¢ÈÐ. 
  
28 º¢¸¢î¨ºÂ¢ý §À¡Ð ¿¡ý µöÅ¡¸ þÕì¸ ÓÊÂ¡Ð.   
29 º¢¸¢î¨º ±ÎìÌõ§À¡Ð ¿¡ý ±ý¨É Á¢¸×õ ¸ðÎô 
À¡ðÎìÌû þÕì¸¢§Èý. 
  
30 ¦¾¡¼÷óÐ º¢¸¢î¨ºÂ¢ø þÕìÌõ §À¡Ð §¿¡öÅ¡ö 
ÀÎÅ¾¢Ä¢ÕóÐ À¡÷òÐì ¦¸¡û¸¢§Èý. 
  
 
 
ÁÕóÐ ¯ð¦¸¡ûÙ¾Ä¢ý ÀÂýÀ¡ðÎ Á¾¢ôÀ£Î 
 Å.±ñ. Å¢É¡ì¸û ´ Á¢ ¯ 
1 ¾¢ÉÓõ ¸¢¨¼ìÌõ ¿Äý  
ÁÕóÐ ¯í¸¨Ç Ì½Á¡ìÌ¸¢ÈÐ ±ýÚ 
¿õÒ¸¢È£÷¸Ç¡? 
   
2 ÁÕòÐÅÕ¼ý ¿øÄ ¯È× 
ÁÕòÐÅÕ¼ý ¯í¸û ¯È× ¯í¸Ç¢ø ¾¡ì¸õ 
²üÀÎòÐ¸¢È¾¡? 
ÁÕòÐÅÕ¼ý ¯ûÇ ¯ÈÅ¡ø ²üÀÎõ ¾¡ì¸õ  
   
3 ¬§Ä¡º¸Ã¢ý ¯È× 
¬§Ä¡º¸Õ¼ý ¯ûÇ ¯È× ¯í¸Ç¢ø ²üÀÎòÐõ 
¾¡ì¸õ 
   
4 ÌÎõÀò¾¢ý Á£ÐûÇ §ÁõÀð¼ ¿õÀ¢ì¨¸ 
¯í¸û ÌÎõÀò¾¢ø ¯ûÇ ´ÕÅ÷ «øÄÐ ¿ñÀ÷ 
¿£í¸û ÁÕóÐ ±ÎòÐì ¦¸¡ûÄ §ÅñÎõ ±É 
¿õÒ¸¢È£÷¸Ç¡? 
   
5 ¾ÎôÒ 
§¿¡ö «øÄÐ §¿¡öì¸¡É «È¢ÌÈ¢¸û Á£ñÎõ 
ÅÕÅ¾¢Ä¢ÕóÐ ÁÕóÐ ±ÎòÐì ¦¸¡ûÙ¾ø ¾Îì¸¢ÈÐ 
±ýÚ ¿õÒ¸¢È£÷¸Ç¡? 
   
6 «Øò¾õ / ÅüÒÚò¾ø 
ÁÕòÐ ±ÎòÐì ¦¸¡ûÇ §ÅñÎ¦ÁýÈ ¿¢÷Àó¾¢ì¸ô 
ÀÎ¸¢È£÷¸Ç¡? ÅÄ¢ÔÚò¾ôÀÎ¸¢È£÷¸Ç¡? 
   
7 Á£ñÎõ ÁÕòÐÅÁ¨ÉÂ¢ø «ÛÁ¾¢ì¸ôÀÎõ ÀÂõ 
¿£í¸û Á£ñÎõ ÁÕòÐÅÁ¨ÉÂ¢ø 
«ÛÁ¾¢ì¸ôÀÎÅ£÷¸û ±ýÚ ÀÂôÀÎ¸¢È£÷¸Ç¡? 
¿£í¸û ¦¾¡¼÷óÐ ÁÕóÐ ¯ð¦¸¡ñ¼¡Öõ º¢Ä 
§¿Ãí¸Ç¢ø ÁÕóÐ ±ÎòÐì ¦¸¡ûÇ §ÅñÊÂ¾¢ø¨Ä 
±ýÚ ¿¢¨Éì¸Ä¡õ «øÄÐ ¾Îì¸Ä¡õ. «¾ü¸¡É 
Óì¸¢Â ¸¡Ã½í¸û ±ýÉ? (þó¾ Á¡¾ò¾¢üÌ) 
þô¦À¡ØÐ ÁüÈÅ÷¸û ÁÕóÐ ¯ð¦¸¡ûÇ ²ý 
   
Å.±ñ. Å¢É¡ì¸û ´ Á¢ ¯ 
¾ÂíÌ¸¢È£÷¸û ±ýÀ¨¾ ¿¡ý ¦º¡ø¸¢§Èý. 
þÅüÚû ²¾¡ÅÐ ¯í¸ÙìÌ ´òÐô§À¡¸¢È¾¡? 
¿£í¸û ÁÕóÐ ¯ð¦¸¡ûÇ ¾ÂíÌÅ¾üÌ ¸¡Ã½õ 
8 ¾¢ÉÓõ ÀÂý þÕôÀ¾¡¸ ¦¾Ã¢ÂÅ¢ø¨Ä 
ÁÕóÐ ¯ð¦¸¡ûÅ¾¡ø Óý§ÉüÈõ þÕôÀ¾¡¸ 
¦¾Ã¢ÂÅ¢ø¨Ä. 
   
9 ÁÕòÐÅÕ¼ý ¯ûÇ ±¾¢÷Á¨ÈÂ¡É ¯È× 
ÁÕòÐÅÕ¼ý ¿õÀ¸ÁüÈ ¯í¸û ¯È× ¯í¸û Á£Ð 
À¡¾¢ô¨À ²üÀÎòÐ¸¢È¾¡? 
   
10 ¬§Ä¡º¸Õ¼ý ¯ûÇ ±¾¢÷Á¨ÈÂ¡É ¯È× 
¬§Ä¡º¸÷ Á£Ð ¿õÀ¸ÁüÈ ¯í¸û ¯È× 
¯í¸û Á£Ð À¡¾¢ô¨À ²üÀÎòÐ¸¢È¾¡? 
   
11 þó¾òÐ¨ÈÂ¢ø ¯ûÇ ¯í¸ÙìÌ ¦¾Ã¢ó¾ ÁÕòÐÅ÷ 
¿£í¸û ÁÕóÐ ±ÎòÐì ¦¸¡ûÅÐ §¾¨Å ±ýÚ 
¿õÀÅ¢ø¨Ä? 
   
12 ÌÎõÀõ / ¿ñÀ÷ ±¾¢÷ôÒ 
¯í¸ÙìÌ Á¢¸×õ §Åñ¼ôÀð¼Å÷ ¿£í¸û ÁÕóÐ 
±ÎòÐì ¦¸¡ûÅ¾üÌ ±¾¢÷ôÒ ¦¾Ã¢Å¢ì¸¢È¡÷. 
   
13 º¢¸¢î¨º ¦ÀÈ Å¡öôÒ ¸¢ðÎÅ¾¢ø ¯ûÇ º¢ì¸ø¸û 
º¢¸¢î¨º ¦ÀÈ Óý «ÛÁ¾¢ ¦ÀÚÅÐ §À¡ýÈÅüÈ¢ø 
º¢ì¸ø º¢ÃÁõ ¯ûÇÐ. 
   
14 §¿¡ÔüÈ¢ÕôÀÐ, ¾÷Á ºí¸¼õ, º¢¸¢î¨º ¦ÀÚÅ¾¢ø 
«ÅÁ¡Éõ 
¿£í¸û ÁÕòÐÅ º¢¸¢î¨º ¦ÀÚÅ¨¾ «ÅÁ¡ÉÁ¡¸ 
¯½÷¸¢È£÷¸Ç¡? 
   
15 Åº¾¢Â¢ý¨Á ´Õ ¾¨¼ 
º¢¸¢î¨ºìÌ ÁÕóÐ ¯ð¦¸¡ûÅ¾üÌ ¯í¸Ç¢¼õ §À¡¾¢Â 
À½Åº¾¢Â¢ø¨ÄÂ¡? 
   
16 §À¡¨¾ô ÀÆì¸õ 
¿£í¸û §À¡¨¾ô¦À¡Õû «øÄÐ ÁÐ 
   
Å.±ñ. Å¢É¡ì¸û ´ Á¢ ¯ 
¯ð¦¸¡û¸¢È£÷¸Ç¡? 
17 §¿¡¨Â ÁÈôÀÐ 
¯í¸ÙìÌ ÁÉ§¿¡ö þÕôÀ¨¾ ²üÚì¦¸¡ûÇ 
ÁÚì¸¢È£÷¸Ç¡? 
   
18 º¢¸¢î¨º / ÁÕóÐ ¯ð¦¸¡ûÅÐ ¾ü§À¡Ð 
§¾¨ÅÂüÈÐ 
¾ü§À¡Ð ÁÕóÐ ¯ð¦¸¡ûÇ §ÅñÎõ ±ýÚ ¿£í¸û 
¿õÀÅ¢ø¨Ä. 
   
19 Àì¸Å¢¨Ç×¸û ÀüÈ¢Â «îºõ 
Àì¸Å¢¨Ç×¸û ÀüÈ¢Â «îºõ ¯í¸ÙìÌ ¯ûÇ¾¡? 
   
20 Á£ñÎõ ÁÕòÐÅÁ¨ÉÂ¢ø §ºÃ Å¢ÕôÀõ 
ÁÕòÐÅÁ¨ÉÂ¢ø ¿£í¸û Á¢¸×õ ¿ÄÁ¡¸ 
¯½÷¸¢È£÷¸Ç¡? 
   
 

 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
